FENC
Fennec Pharmaceuticals Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Fennec Pharmaceuticals (FENC) Stock: Buy, Sell, or Hold?
$10.90
+0.26 (+2.44%)
▲
5d:
+16.08%
30d:
+9.22%
90d:
-7.0%
QUANTITATIVE VERDICT
BUY
MODERATE Confidence (63%)
Quality Score
54/100
Position
EXTENDED
30-Day Fair Range
$10.07 – $10.76
Position: EXTENDED
Forward P/E & Valuation
11.5x
FAIR
vs 10.8x historical avg
Wall Street Target
$17.20
+57.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$9.20 / $11.64
Trend: Sideways
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
💡 BUY OPPORTUNITY: FENC shows positive signals but monitor for confirmation. Market pricing in 2.0% annual growth which appears achievable. Moderate conviction.
Get Alerted When FENC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$19.94
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$12.38
12.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FENC is currently trading at $10.90, which is considered extended relative to its 30-day fair value range of $10.07 to $10.76. The stock's valuation (Forward PE: 11.5) is in line with its historical norms (10.8). At these levels, the market is pricing in 2.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FENC is showing sideways momentum. Immediate support is located at $9.20, while resistance sits at $11.64.
Market Sentiment: FENC scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $17.20 (+57.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, FENC is showing sideways momentum. Immediate support is located at $9.20, while resistance sits at $11.64.
Market Sentiment: FENC scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $17.20 (+57.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.07 -
$10.76
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.9%
Trading Range & Key Levels
30-Day Trading Range
$10.07 -
$10.76
Current vs Trading Range
EXTENDED
Support Level
$9.20
Resistance Level
$11.64
Current Trend
Sideways
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.8% below Wall St target ($17.20)
- NEUTRAL: Market pricing in 2.0% annual earnings growth - fairly valued
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
11.50
Wall Street Target
$17.20
(+57.8%)
Revenue Growth (YoY)
85.2%
Profit Margin
-5.5%
Valuation Premium vs History
+2.0% premium
PE vs Historical
11.5 vs 10.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.0%
(market-implied from PE analysis)
1-Year Target
$11.12
(+2%)
2-Year Target
$11.34
(+4%)
3-Year Target
$11.57
(+6%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$10.87
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 194.4%)
$63.54
(+483%)
Base:
(SPY PE: 11.5, Growth: 194.4%)
$36.79
(+238%)
Bear:
(PE: 9.8, Growth: 194.4%)
$31.27
(+187%)
Share FENC Analysis
Share this live FENC analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (FENC)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary:
Fennec Pharmaceuticals reported Q3 sales growth of 56% driven by increased patient enrollment and commercial expansion. Net product sales reached $19.4 million, with adjusted EBITDA at $5.8 million.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 6:00 AM ET
Data refreshes hourly during market hours. Next update: 7:00 AM
Data refreshes hourly during market hours. Next update: 7:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FENC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 65 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 37 SELL |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$689 | 58 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
17 analysts |
$35 | 46 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive FENC Research Pages
